The Journal of urology
Enzalutamide Monotherapy for the Treatment of Prostate Cancer With High-Risk Biochemical Recurrence: EMBARK Secondary End Points.
Neal D Shore, Ugo De Giorgi, Ronald F Tutrone, James L Bailen, Erik P M Roos, Ján Kliment, Gavin Marx, Lawrence I Karsh, Miguel Ramirez-Backhaus, Edward M Uchio, Stéphane Supiot, Yiyun Tang, Brad Rosbrook, Gabriel P Haas, Matt Rosales
Published: 202510.1097/JU.0000000000004879
Abstract
PURPOSE: Primary analysis of the phase 3 EMBARK trial reported efficacy and safety outcomes for enzalutamide monotherapy in patients with high-risk biochemical recurrence. Here, we report secondary end points for enzalutamide monotherapy vs leuprolid…
Preview only. Read the full abstract at the source